Overview
Dr. Emmanuel Walter, MD, MPH, Professor of Pediatrics, serves as the Duke Human Vaccine Institute (DHVI) Chief Medical Officer and directs the Duke Vaccine and Trials Unit. In these roles, Dr. Walter provides strategic and operational leadership for clinical research conducted at the Institute. In addition, he provides oversight of regulatory compliance for DHVI clinical research activities.
Dr. Walter has dedicated his career to advancing research and clinical practice in vaccinology, infectious diseases, and child health. He currently serves as the principal investigator for the Duke Clinical Core of the Collaborative Influenza Vaccine Innovations Centers (CIVICs) funded by the National Institute of Allergy and Infectious Diseases (NIAID). The goal of this work is to evaluate promising next generation influenza vaccine candidates in Phase I and Phase I/II clinical trials and human challenge studies. He is also the Duke Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment Project which conducts studies to identify risk factors and preventive strategies for adverse events following immunization, particularly in special populations. Lastly, he is the Principal Investigator for the CDC-funded coordinating center of the influenza and other respiratory virus vaccine effectiveness network. This work provides national estimates for influenza and other respiratory virus vaccine effectiveness in persons presenting with respiratory illness in the ambulatory setting.
Dr. Walter's focused area of interest include vaccine development, vaccine safety, vaccine effectiveness, vaccine coverage, prevention and treatment of infectious diseases.
Current Appointments & Affiliations
In the News
View All News
Recent Publications
Preventing Postvaccination Presyncope and Syncope in Adolescents: A Randomized Controlled Trial of a Clinic-Based Intervention.
Journal Article J Pediatr · June 2026 OBJECTIVE: To study the impact of a combined intervention using Buzzy plus simultaneous distraction (playing video games on a tablet) on the incidence of postvaccination presyncope and syncope. STUDY DESIGN: We performed a randomized-controlled trial of a ... Full text Link to item CiteInfluenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season.
Journal Article medRxiv · March 26, 2026 BACKGROUND: Influenza A(H1N1)pdm09 and A(H3N2) viruses predominated during the 2024-25 U.S. influenza season. We estimated influenza vaccine effectiveness (VE) in the United States against mild-to-moderate outpatient influenza illness by influenza type and ... Full text Link to item CiteThe neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances.
Journal Article Vaccine · March 19, 2026 In the Coronavirus Variant Immunologic Landscape Trial (COVAIL) conducted in the United States in 2022-2023, 985 participants received a second COVID-19 booster with one of twelve monovalent or bivalent mRNA inserts. Pseudovirus serum inhibitory dilution 5 ... Full text Link to item CiteRecent Grants
CIVICS Component C - Option 13B.1 Biorepository
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2026 - 2030Duke University Maternal-Fetal Medicine Units (MFMU) Network Clinical Center
ResearchCollaborating Investigator · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2023 - 2030CIVICS Component C - Option 16 EA - COBRA
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2029View All Grants